The University of California, Davis, has launched the to advance basic knowledge about the mechanisms of psychedelics and translate it into safe and effective treatments for diseases such as depression, post-traumatic stress disorder, addiction, Alzheimer’s disease and Parkinson’s disease, among others. The new institute will bring together scientists across a range of disciplines and partner with the pharmaceutical industry to ensure that key discoveries lead to new medicines for patients.
“Psychedelics have a unique ability to produce long-lasting changes in the brain that are relevant to treating numerous conditions,” said , associate professor in the Department of Chemistry and the Department of Biochemistry and Molecular Medicine at 51ԹϺ Davis. “If we can harness those beneficial properties while engineering molecules that are safer and more scalable, we can help a lot of people.”
Olson will be the founding director of the new institute, with , associate professor in the Department of Neurology, serving as associate director. In 2018, Olson and Gray published an influential study in demonstrating that psychedelics promote neuroplasticity — the growth of new neurons and formation of neural connections.
“Neuronal atrophy is a key factor underlying many diseases,” said Gray, “and the ability of psychedelics to promote the growth of neurons and new connections in the brain could have broad therapeutic implications.”
A historic investment
The 51ԹϺ Davis institute will be funded in part by a contribution of approximately $5 million from the deans of the College of Letters and Science and the School of Medicine, the vice chancellor for Research, and the Office of the Provost. While other psychedelic science centers have been formed across the country with gifts from philanthropists, the 51ԹϺ Davis institute is notable for also being supported by substantial university funds.
“We wanted to put our money where our mouth is and demonstrate our commitment to this space,” said , dean of the College of Letters and Science overseeing the new institute. Additionally, philanthropic donations as well as grants and sponsored research agreements from the federal government, private foundations and industry partners will support the mission of the institute.
“51ԹϺ Davis has been leading the development of new medicines based on psychedelic research, and together with philanthropists, granting agencies and industrial partners, I’m confident that we can produce major benefits for society,” Atekwana said.
Leveraging strengths in chemistry, neuroscience and medicine
The institute will leverage the extraordinary breadth of expertise in the neuroscience community at 51ԹϺ Davis, which includes nearly in centers, institutes and departments across the Davis and Sacramento campuses. Researchers will be able to work on every aspect of psychedelic science, from molecules and cells through to human clinical trials.
“Combining the considerable expertise of 51ԹϺ Davis’ pioneering basic research teams, world-class neuroscientists and our nationally recognized medical center is a formula for success that we trust will result in groundbreaking discoveries that will help patients regionally and worldwide,” said , dean of the School of Medicine who partnered with Atekwana to support the new institute.
The Institute for Psychedelics and Neurotherapeutics was specifically designed to facilitate collaborations across campus, such as that between Olson and , a professor in the Department of Biochemistry and Molecular Medicine. In 2021, their publication in was voted the No. 2 biomedical research discovery of the year by .
A unique feature of the 51ԹϺ Davis institute will be its focus on chemistry and the development of novel neurotherapeutics.
“Psychedelics have a lot of therapeutic potential, but we can do better,” said Olson. In 2020, his group published a paper in describing the first nonhallucinogenic analogue of a psychedelic compound capable of promoting neuroplasticity and producing antidepressant and anti-addictive effects in preclinical models. Olson calls these molecules because of their effect on neuron growth. Novel molecules tailored to specific disease indications could offer substantial benefits and open doors to partnerships with industry by solving many issues currently faced by traditional psychedelics related to safety, scalability and intellectual property.
Bridging academia and industry
Major challenges exist for translating academic discoveries and promising lead compounds into drug candidates for clinical use. To bridge this gap, the institute aims to spin out companies and build strong collaborations with pharmaceutical partners through licensing and sponsored research agreements. , a company co-founded by Olson, has licensed 51ԹϺ Davis technology and supported several cutting-edge basic research projects on campus related to psychoplastogens and neuroplasticity. Recently, Delix was named a top academic spinout company by and , and in 2021, was named one of the by Fierce biotech.
“Our relationship with 51ԹϺ Davis has been very synergistic, and we are excited to continue that partnership,” said , the CEO of Delix. “Getting the brightest and most creative minds from academia and industry to work together is our best chance to solve many of the grand challenges facing society today.”
Media Resources
Media Contacts:
- David Olson, Chemistry, deolson@ucdavis.edu
- Andy Fell, News and Media Relations, 530-304-8888, ahfell@ucdavis.edu